Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛帝宮母嬰健康股份有限公司 AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

PROFIT WARNING

This announcement is made by Aidigong Maternal & Child Health Limited (the "Company" and together with its subsidiaries, the "Group") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "Board") of directors (the "Directors") of the Company wishes to inform the shareholders (the "Shareholders") of the Company and potential investors that the Group is expected to record a consolidated net loss of not more than HK\$180 million for the year ended 31 December 2022 (the "FY2022"), while the net profit for the same period in 2021 was approximately HK\$35 million.

The net loss for the financial year was mainly due to (i) finance costs of approximately HK\$63 million for the FY2022, which included non-cash expenses of approximately HK\$19 million for interest on lease liabilities; (ii) the increase in non-cash expenses related to the share incentive scheme of approximately HK\$40 million; (iii) the decrease in gain on disposal of subsidiaries and associates for the FY2022 as compared with the previous financial year; (iv) disposed real estate business that incurred expenses prior to its disposal; and (v) impact of the COVID-19 pandemic on all of the Group's postpartum care centre stores in varying degrees which resulted in the customers being unable to check in as scheduled, coupled with increased investment costs for store opening of new brand for the FY2022, thereby affecting the gross profit and profit.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company on the information currently available to the Company and the unaudited consolidated management accounts of the Group for the FY2022, which have not been determined or reviewed by the Company's external auditors or the audit committee of the Company and may therefore be subject to change.

The audited annual results announcement of the Company for the FY2022 is expected to be published by the end of this month.

Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board

Aidigong Maternal & Child Health Limited

Zhu Yufei

Chairman

Hong Kong, 20 March 2023

As at the date of this announcement, the Board comprises Ms. Zhu Yufei, Mr. Cheung Wai Kuen, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Guo Qifei and Ms. Liang Linmin as non-executive Directors; and Ms. Yu Lin, Mr. Wong Yiu Kit, Ernest, Mr. Huang Wenhua and Mr. Wang Qingyu as independent non-executive Directors.